Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB151
- Development stage
- Preclinical
- Lead developer
- Neurodexis11 Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PB151 is a selective, brain-penetrant, and orally bioavailable small molecule inhibitor of histone deacetylase 11 (HDAC11) being developed by Neurodexis11 Therapeutics (a spinout from Massachusetts General Hospital and Harvard Medical School) for the treatment of Alzheimer's disease and other central nervous system (CNS) disorders. By selectively targeting HDAC11, PB151 aims to modulate neuroinflammation and gene regulation pathways. In preclinical models of Alzheimer's disease, including 5XFAD and Tau P301S mice, PB151 has demonstrated efficacy in reducing amyloid and tau pathology, decreasing key inflammatory cytokines, and restoring cognitive function.
02
Targets
HDAC11 (Histone Deacetylase 11)
Beyond the preview
Go deeper on PB151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB151.